Send to

Choose Destination
Therapie. 2016 Feb;71(1):1-13, 15-26. doi: 10.1016/j.therap.2016.01.001. Epub 2016 Feb 3.

Translational research on cognitive and behavioural disorders in neurological and psychiatric diseases.

[Article in English, French]

Author information

Inserm UMRS 1127, CIC 1422, CNRS UMR 7225, département des maladies du système nerveux, hôpital Pitié-Salpêtrière, AP-HP, UPMC - université Paris 06, Sorbonne universités, bâtiment ICM, 47/83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address:
Lundbeck SAS, 92445 Issy-les-Moulineaux, France.
Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU, université de Lille, 59000 Lille, France.
Service de pharmacologie clinique et pharmacovigilance, hôpital Timone, AP-HM, Aix-Marseille université, UMR CNRS 7289, institut de neurosciences Timone, pharmacologie intégrée et interface clinique et industriel, 13385 Marseille, France.
Institut de pharmacologie moléculaire et cellulaire, UMR7275 CNRS-UNS, Sophia Antipolis, 06560 Nice, France.
Inserm UMRS1178, université Paris-Saclay, université Paris-Sud, CESP, 92290 Châtenay-Malabry, France.
EA 7280, UFR médecine, service de neurologie, CHU Gabriel-Montpied, CHU de Clermont-Ferrand, université Clermont 1, 69003 Clermont-Ferrand, France.
Institut des maladies neurodégénératives, UMR 5293, CNRS, université de Bordeaux, 33000 Bordeaux, France.
Inserm, laboratoire de physiopathologie des maladies psychiatriques, centre de psychiatrie et neurosciences U894, institut de psychiatrie (GDR 3557), centre hospitalier Sainte-Anne, Human Histopathology and Animal Models, Infection and Epidemiology Department, Institut Pasteur, université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France.
Inserm, AVIESAN, institut thématique multi-organismes neurosciences, sciences cognitives, neurologie, psychiatrie, 75013 Paris, France.
Inserm, laboratoire de neurosciences expérimentales et cliniques, LNEC Inserm U-1084, Inserm CIC-1402, pharmacologie clinique et vigilances, CHU de Poitiers, université de Poitiers, 86021 Poitiers, France.
Inserm, EPHE, unité U923, GIP Cyceron, CHU de Caen, université Caen-Basse-Normandie, 14074 Caen, France.
Sanofi-Genzyme R&D, 91385 Chilly-Mazarin, France.


The important medical and social burden of nervous system diseases contrasts with the currently limited therapeutic armamentarium and with the difficulty encountered in developing new therapeutic options. These failures can be explained by the conjunction of various phenomena related to the limitations of animal models, the narrow focus of research on precise pathophysiological mechanisms, and methodological issues in clinical trials. It is perhaps the paradigm itself of the way research is conducted that may be the real reason for our incapacity to find effective strategies. The purpose of this workshop was to define overall lines of research that could lead to the development of effective novel therapeutic solutions. Research has long focused on diseases per se rather than on cognitive and behavioural dimensions common to several diseases. Their expression is often partial and variable, but can today be well-characterised using neurophysiological or imaging methods. This dimensional or syndromic vision should enable a new insight to the question, taking a transnosographic approach to re-position research and to propose: translational models exploring the same functions in animal models and in humans; identification of homogeneous groups of patients defined according to the clinical, anatomico-functional and molecular characteristics; and preclinical and clinical developments enriched by the use of cognitive-behavioural, biological neurological, and imaging biomarkers. For this mutation to be successful, it must be accompanied by synchronised action from the public authorities and by ad hoc measures from the regulatory agencies.


Behaviour; Cognition; Medical devices; Medications; Neurology; Pharmacology; Psychiatrics

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center